What is the specific use of acotinib/acalatinib in the treatment of vaginal discharge?

Acalabrutinib (Acalabrutinib) is a new generation BTK inhibitor that is widely used to treat mantle cell lymphoma (MCL), an aggressive B-cell non-Hodgkin lymphoma. Compared with the first-generation BTK inhibitor ibrutinib, acotinib is more selective and can maintain effective inhibition of B cell signaling pathways while reducing off-target side effects. It is one of the important targeted drugs currently used to treat MCL. For adult patients with relapsed or refractory MCL, the standard dose of acotinib is 100 mg orally every 12 hours until disease progression or patients cannot tolerate side effects. This single-drug regimen has been widely used in many countries and is listed as one of the recommended drugs in guidelines.

In newly treated MCL patientsAcotinib can also be used in combination with traditional chemotherapy and immunotherapy, and its combination regimen has now become a cutting-edge clinical treatment strategy in many countries. The specific plan is to combine acotinib with bendamustine and rituximab. In this combination regimen, patients began taking acotinib at 100 mg every 12 hours starting on the first day of the first cycle and continued until progression or unacceptable toxicity. At the same time, the chemotherapy drug bendamustine was administered at a dose of 90 mg/m² on days 1 and 2 of cycle 1, while rituximab was administered intravenously at a dose of 375 mg/m² on day 1 of cycle 1. This triple regimen generally lasts for six 28-day cycles. After the first 6 cycles, if the patient achieves partial response (PR) or complete response (CR), he or she can enter the maintenance treatment phase of rituximab, which is usually used on the 1st day of each cycle and continues from the 8th cycle to up to the 30th cycle, with a total of up to 12 maintenance doses to extend the response time and delay recurrence.

Reference materials:https://www.calquence.com/